Hemodialysis Graft Dysfunction
Conditions
Keywords
Vascular Access Graft Failure, Venous Neointimal Hyperplasia(VNH), Hemodialysis
Brief summary
This study is designed to confirm the safety of the proposed dose and schedule of ABI-007 for hemodialysis patients with vascular access device failure, and to obtain preliminary data on the effectiveness of such treatment.
Detailed description
This is an open-label, pilot, phase II study to assess the feasibility of administering ABI-007 intravenously \[IV\] over 3-5 minutes to patients with hemodialysis graft dysfunction (i.e., either a thrombosed polytetrafluoroethylene (PTFE) graft, or a patent but dysfunctional PTFE graft). Patients with graft dysfunction who are successfully treated with angioplasty will start treatment after angioplasty or during their first dialysis through the graft following intervention, and will receive 3 subsequent treatments of ABI-007 at 35 mg/m\^2 on weeks 5, 13 and 21.
Interventions
DRUGABI-007
Sponsors
Celgene
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Thrombosed graft within the past 7 days or a patent but dysfunctional polytetrafluoroethylene (PTFE) graft (identified by any means) with a stenosis of greater than 50% at the graft-vein anastomosis or within 8 centimeters of the graft-vein anastomosis which will be referred to as the index lesion. Following angioplasty patients must have residual stenosis of less than 20% post angioplasty for the index lesion and for all other stenoses; also index lesion must be located in the arm. PTFE graft requiring angioplasty must be at least 30 days old. * Male or non-pregnant and non-lactating female, and ≥ 18 years of age. * Patient or guardian has provided a signed written informed consent for the administration of ABI-007 (post-angioplasty or at the time of first dialysis through the new graft) using a form that is approved by the local IRB/ethics committee of the investigative site. * Patient or his/her legally authorized representative or guardian has been informed about the nature of the study, and has agreed to participate in the study, and signed the Informed Consent form prior to participation in any study-related activities.
Exclusion criteria
* Use of a stent at the time of current angioplasty or at any previous time in the index lesion. * No perforation at the time of current angioplasty. * Thrombosed graft for more than 7 days. * Patient has the following blood counts at baseline: * Absolute neutrophil count (ANC) \< 2.0\*10\^9/L; * platelets \< 100\*10\^9/L; * Hemoglobin (Hgb) \< 9 g/dL. * Patient has the following blood chemistry levels at baseline: * Aspartate transaminase (AST or SGOT), alanine transaminase (ALT or SGPT) \> 2.5x upper limit of normal range (ULN); * total bilirubin ≥ upper limit of normal (ULN); * Unable to give informed consent, or for whom informed consent cannot be obtained from a legal guardian. * Women who are pregnant and women of child bearing potential who do not use adequate contraception. * 2 procedures of percutaneous or surgical intervention on the PTFE graft within the previous 90 days. * Previous participation in another study with any investigational drug or device within the past 30 days or current enrollment in any other clinical protocol or investigational trial. * Patient has a life expectancy of less than 6 months. * Intended kidney transplant within 6 months of enrollment in the study * Any significant medical condition which in the investigators opinion may interfere with the patients optimal participation in the study. * Patient is, in the investigator's opinion, unlikely to be able to complete the study through the End of Study (EOS) visit. * Patient has a history of allergy or hypersensitivity to the study drug. * Documented hypercoagulable state requiring anti-coagulation (protein S, protein C, antiphospholipid; anticoagulation on an empiric basis for graft thromboses in not a contradiction). * Patient is human immunodeficiency virus (HIV) positive. * Patient is currently receiving other chemotherapy drug(s).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Stenosis (%) of a Non-index Lesion Using Angiography at Month 12 | 12 months | Non-indexed lesion with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the non-index lesion is measured by angiography. Three non-index lesions are reported: central vein, intragraft and arterial anastomosis. |
| Stenosis (%) of a Non-index Lesion Using Angiography at Week 12 | 12 weeks | Non-indexed lesion with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the non-index lesion is measured by angiography. Three non-index lesions are reported: central vein, intragraft and arterial anastomosis. |
| Stenosis (%) of a Non-index Lesion Using Angiography at Week 24 | 24 weeks | Non-indexed lesion with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the non-index lesion is measured by angiography. Three non-index lesions are reported: central vein, intragraft and arterial anastomosis. |
| Stenosis (%) of a Non-index Lesion Using Angiography at Month 9 | 9 months | Non-indexed lesion with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the non-index lesion is measured by angiography. Three non-index lesions are reported: central vein, intragraft and arterial anastomosis. |
| Percentage of Participants With Discontinued, Delayed or Interrupted Therapy | up to week 21 | Percentage of participants who had discontinued therapy or had a delayed dose or an interrupted (omitted) dose due to toxicities/adverse events. |
| Percentage of Participants Without Graft Failure or Need for Intervention | 24 weeks | Graft failure is defined as graft thrombosis, loss of vascular access function, or \>50% stenosis of the index lesion at the time of a regularly scheduled angiographic assessment. |
| Stenosis (%) of the Index Lesion at Venous Anastomosis Using Angiography at Week 12 | 12 weeks | Indexed lesion must be located in the arm and is a polytetrafluoroethylene (PTFE) thrombosed graft or a patent but dysfunctional PTFE graft with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the index lesion is measured by angiography. |
| Stenosis (%) of the Index Lesion at Venous Anastomosis Using Angiography at Week 24 | 24 weeks | Indexed lesion must be located in the arm and is a polytetrafluoroethylene (PTFE) thrombosed graft or a patent but dysfunctional PTFE graft with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the index lesion is measured by angiography. |
| Stenosis (%) of the Index Lesion at Venous Anastomosis Using Angiography at Month 9 | 9 months | Indexed lesion must be located in the arm and is a polytetrafluoroethylene (PTFE) thrombosed graft or a patent but dysfunctional PTFE graft with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the index lesion is measured by angiography. |
| Stenosis (%) of the Index Lesion at Venous Anastomosis Using Angiography at Month 12 | 12 months | Indexed lesion must be located in the arm and is a polytetrafluoroethylene (PTFE) thrombosed graft or a patent but dysfunctional PTFE graft with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the index lesion is measured by angiography. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Kaplan Meier Estimates for Time to Graft Failure or Intervention | up to 12 months | The time to graft failure or intervention was defined as the time from first dose of study drug to the first time graft failure or intervention. Participants who did not have graft failure or intervention at the end of the study were censored at the last known time that the participant had angiography. |
| Percentage of Participants With Patency of Index and Non-Index Lesions at 24 Weeks | 24 weeks | The patency (unblocking) for index lesions is defined as \<50% of stenosis and no PFTE graft thrombosis at 24 weeks. The patency for non-index lesions is defined as \<50% of stenosis and no new non-index lesions at 24 weeks. |
| Participants With Arthrosclerotic Cardiovascular Complications | up to week 25 | Counts of participants who had treatment-emergent arthrosclerotic cardiovascular complications, specifically myocardial infarction, arterial thromboses, or cerebrovascular events. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| ABI-007 ABI-007 35 mg/m\^2 given intravenously (IV) into the arteriovenous (AV) graft within 96 hours after angioplasty, followed by repeat treatment during weeks 5, 13 and 21 | 9 |
| Total | 9 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Adverse Event | 2 |
| Overall Study | Other | 2 |
| Overall Study | Study cancellation | 3 |
Baseline characteristics
| Characteristic | ABI-007 |
|---|---|
| Age, Continuous | 67.6 years STANDARD_DEVIATION 8.16 |
| Age, Customized <65 years | 4 participants |
| Age, Customized >=65 years | 5 participants |
| Race/Ethnicity, Customized American Indian or Alaska Native | 0 participants |
| Race/Ethnicity, Customized Asian | 0 participants |
| Race/Ethnicity, Customized Black of African heritage | 7 participants |
| Race/Ethnicity, Customized Native Hawaiian or Other Pacific Islander | 0 participants |
| Race/Ethnicity, Customized Other | 0 participants |
| Race/Ethnicity, Customized White, Hispanic or Latino | 0 participants |
| Race/Ethnicity, Customized White, Non-Hispanic and Non-Latino | 2 participants |
| Sex: Female, Male Female | 6 Participants |
| Sex: Female, Male Male | 3 Participants |
| Weight | 71.78 kg STANDARD_DEVIATION 13.271 |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 7 / 9 |
| serious Total, serious adverse events | 6 / 9 |
Outcome results
Primary
Percentage of Participants With Discontinued, Delayed or Interrupted Therapy
Percentage of participants who had discontinued therapy or had a delayed dose or an interrupted (omitted) dose due to toxicities/adverse events.
Time frame: up to week 21
Population: Treated population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| ABI-007 | Percentage of Participants With Discontinued, Delayed or Interrupted Therapy | Delayed dose | 44 percentage of participants |
| ABI-007 | Percentage of Participants With Discontinued, Delayed or Interrupted Therapy | Interrupted | 0 percentage of participants |
| ABI-007 | Percentage of Participants With Discontinued, Delayed or Interrupted Therapy | Discontinued therapy | 33 percentage of participants |
Primary
Percentage of Participants Without Graft Failure or Need for Intervention
Graft failure is defined as graft thrombosis, loss of vascular access function, or \>50% stenosis of the index lesion at the time of a regularly scheduled angiographic assessment.
Time frame: 24 weeks
Population: Evaluable participants who were treated
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| ABI-007 | Percentage of Participants Without Graft Failure or Need for Intervention | 0 percentage of participants |
Primary
Stenosis (%) of a Non-index Lesion Using Angiography at Month 12
Non-indexed lesion with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the non-index lesion is measured by angiography. Three non-index lesions are reported: central vein, intragraft and arterial anastomosis.
Time frame: 12 months
Population: Treated population of participants with a non-index lesion.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| ABI-007 | Stenosis (%) of a Non-index Lesion Using Angiography at Month 12 | Central vein | NA percentage of stenosis |
| ABI-007 | Stenosis (%) of a Non-index Lesion Using Angiography at Month 12 | Intragraft | 50.0 percentage of stenosis |
| ABI-007 | Stenosis (%) of a Non-index Lesion Using Angiography at Month 12 | Arterial anastomosis | 25.0 percentage of stenosis |
Primary
Stenosis (%) of a Non-index Lesion Using Angiography at Month 9
Non-indexed lesion with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the non-index lesion is measured by angiography. Three non-index lesions are reported: central vein, intragraft and arterial anastomosis.
Time frame: 9 months
Population: Treated population of participants with a non-index lesion.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ABI-007 | Stenosis (%) of a Non-index Lesion Using Angiography at Month 9 | Central vein | 65.0 percentage of stenosis | — |
| ABI-007 | Stenosis (%) of a Non-index Lesion Using Angiography at Month 9 | Intragraft | 57.5 percentage of stenosis | Standard Deviation 10.61 |
| ABI-007 | Stenosis (%) of a Non-index Lesion Using Angiography at Month 9 | Arterial anastomosis | 25.0 percentage of stenosis | — |
Primary
Stenosis (%) of a Non-index Lesion Using Angiography at Week 12
Non-indexed lesion with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the non-index lesion is measured by angiography. Three non-index lesions are reported: central vein, intragraft and arterial anastomosis.
Time frame: 12 weeks
Population: Treated population of participants with a non-index lesion.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ABI-007 | Stenosis (%) of a Non-index Lesion Using Angiography at Week 12 | Central vein | 50.0 percentage of stenosis | — |
| ABI-007 | Stenosis (%) of a Non-index Lesion Using Angiography at Week 12 | Intragraft | 35.0 percentage of stenosis | Standard Deviation 35.36 |
| ABI-007 | Stenosis (%) of a Non-index Lesion Using Angiography at Week 12 | Arterial anastomosis | 25.0 percentage of stenosis | — |
Primary
Stenosis (%) of a Non-index Lesion Using Angiography at Week 24
Non-indexed lesion with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the non-index lesion is measured by angiography. Three non-index lesions are reported: central vein, intragraft and arterial anastomosis.
Time frame: 24 weeks
Population: Treated population of participants with a non-index lesion.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ABI-007 | Stenosis (%) of a Non-index Lesion Using Angiography at Week 24 | Central vein | 40.0 percentage of stenosis | — |
| ABI-007 | Stenosis (%) of a Non-index Lesion Using Angiography at Week 24 | Intragraft | 45.0 percentage of stenosis | Standard Deviation 21.21 |
| ABI-007 | Stenosis (%) of a Non-index Lesion Using Angiography at Week 24 | Arterial anastomosis | 27.5 percentage of stenosis | — |
Primary
Stenosis (%) of the Index Lesion at Venous Anastomosis Using Angiography at Month 12
Indexed lesion must be located in the arm and is a polytetrafluoroethylene (PTFE) thrombosed graft or a patent but dysfunctional PTFE graft with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the index lesion is measured by angiography.
Time frame: 12 months
Population: Treated population of participants with an index lesion at this site.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| ABI-007 | Stenosis (%) of the Index Lesion at Venous Anastomosis Using Angiography at Month 12 | 95.0 percentage of stenosis |
Primary
Stenosis (%) of the Index Lesion at Venous Anastomosis Using Angiography at Month 9
Indexed lesion must be located in the arm and is a polytetrafluoroethylene (PTFE) thrombosed graft or a patent but dysfunctional PTFE graft with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the index lesion is measured by angiography.
Time frame: 9 months
Population: Treated population of participants with an index lesion at this site.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| ABI-007 | Stenosis (%) of the Index Lesion at Venous Anastomosis Using Angiography at Month 9 | 69.3 percentage of stenosis | Standard Deviation 4.04 |
Primary
Stenosis (%) of the Index Lesion at Venous Anastomosis Using Angiography at Week 12
Indexed lesion must be located in the arm and is a polytetrafluoroethylene (PTFE) thrombosed graft or a patent but dysfunctional PTFE graft with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the index lesion is measured by angiography.
Time frame: 12 weeks
Population: Treated population of participants with an index lesion at this site.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| ABI-007 | Stenosis (%) of the Index Lesion at Venous Anastomosis Using Angiography at Week 12 | 61.7 percentage of stenosis | Standard Deviation 32.51 |
Primary
Stenosis (%) of the Index Lesion at Venous Anastomosis Using Angiography at Week 24
Indexed lesion must be located in the arm and is a polytetrafluoroethylene (PTFE) thrombosed graft or a patent but dysfunctional PTFE graft with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the index lesion is measured by angiography.
Time frame: 24 weeks
Population: Treated population of participants with an index lesion at this site.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| ABI-007 | Stenosis (%) of the Index Lesion at Venous Anastomosis Using Angiography at Week 24 | 79.0 percentage of stenosis | Standard Deviation 11.4 |
Secondary
Kaplan Meier Estimates for Time to Graft Failure or Intervention
The time to graft failure or intervention was defined as the time from first dose of study drug to the first time graft failure or intervention. Participants who did not have graft failure or intervention at the end of the study were censored at the last known time that the participant had angiography.
Time frame: up to 12 months
Population: Treated population
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| ABI-007 | Kaplan Meier Estimates for Time to Graft Failure or Intervention | 11.4 weeks |
Secondary
Participants With Arthrosclerotic Cardiovascular Complications
Counts of participants who had treatment-emergent arthrosclerotic cardiovascular complications, specifically myocardial infarction, arterial thromboses, or cerebrovascular events.
Time frame: up to week 25
Population: Treated population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| ABI-007 | Participants With Arthrosclerotic Cardiovascular Complications | >=1 arthrosclerotic cardiovascular complication | 4 participants |
| ABI-007 | Participants With Arthrosclerotic Cardiovascular Complications | Bradycardia | 1 participants |
| ABI-007 | Participants With Arthrosclerotic Cardiovascular Complications | Hypotension | 1 participants |
| ABI-007 | Participants With Arthrosclerotic Cardiovascular Complications | Hypertrophic obstructive cardiomyopathy | 1 participants |
| ABI-007 | Participants With Arthrosclerotic Cardiovascular Complications | Carotid artery stenosis | 1 participants |
| ABI-007 | Participants With Arthrosclerotic Cardiovascular Complications | Cerebrovascular accident | 1 participants |
| ABI-007 | Participants With Arthrosclerotic Cardiovascular Complications | Cardiovascular disorder | 1 participants |
Secondary
Percentage of Participants With Patency of Index and Non-Index Lesions at 24 Weeks
The patency (unblocking) for index lesions is defined as \<50% of stenosis and no PFTE graft thrombosis at 24 weeks. The patency for non-index lesions is defined as \<50% of stenosis and no new non-index lesions at 24 weeks.
Time frame: 24 weeks
Population: Treated Population of evaluable participants
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| ABI-007 | Percentage of Participants With Patency of Index and Non-Index Lesions at 24 Weeks | Index lesion | 14 percentage of participants |
| ABI-007 | Percentage of Participants With Patency of Index and Non-Index Lesions at 24 Weeks | Non-Index lesions | 57 percentage of participants |